このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Sarepta Therapeutics バランスシートの健全性
財務の健全性 基準チェック /36
Sarepta Therapeuticsの総株主資本は$961.2M 、総負債は$1.2Bで、負債比率は128.9%となります。総資産と総負債はそれぞれ$3.2Bと$2.3Bです。
主要情報
128.9%
負債資本比率
US$1.24b
負債
| インタレスト・カバレッジ・レシオ | n/a |
| 現金 | US$1.39b |
| エクイティ | US$961.19m |
| 負債合計 | US$2.26b |
| 総資産 | US$3.22b |
財務の健全性に関する最新情報
Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15
Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Recent updates
Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry?
May 09Sarepta: The DMD Leader
Apr 26Sarepta: Still A Solid Long-Term Bet On Sales And Next Generation Treatments
Feb 09Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Feb 07A Look At The Intrinsic Value Of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Dec 06Sarepta: Revenue Keeps Rising While We Wait For Functional Data
Nov 01Health Check: How Prudently Does Sarepta Therapeutics (NASDAQ:SRPT) Use Debt?
Nov 01財務状況分析
短期負債: SRPTの 短期資産 ( $2.5B ) が 短期負債 ( $608.7M ) を超えています。
長期負債: SRPTの短期資産 ( $2.5B ) が 長期負債 ( $1.7B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: SRPT総負債よりも多くの現金を保有しています。
負債の削減: SRPTの負債対資本比率は、過去 5 年間で31.6%から128.9%に増加しました。
債務返済能力: SRPTの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。
インタレストカバレッジ: SRPTの負債に対する 利息支払い が EBIT によって 十分にカバーされている かどうかを判断するにはデータが不十分です。